List/Grid Tag Archives: cytokines
Antibodies and other bits
Big antibody news
The “third generation” humanized anti-GD2 antibody with protein fusion of IL2 to the antibody has completed Phase I and II clinical trials for melanoma and neuroblastoma, and is now ready for use in Phase III clinical trials. The license for hu14.18-IL2 was just acquired by a small biotech in Vienna called Apeiron. The license was acquired from Merck.
Apeiron’s press ...
Biggest news for neuroblastoma in a decade: ch14.18 plus GM-CSF and IL2
Rare news
A disease that afflicts only 350 children per year in the US (in the high-risk form) does not make headlines very often. But after the September 30, 2010 publication of the New England Journal of Medicine article revealing the results of the phase III chimeric antibody trial (ch14.18 given with two cytokines GM-CSF and IL2), neuroblastoma was all over the news including prime time national ...
New frontline high-risk neuroblastoma trial includes MIBG transplant
Pilot study: 131I-MIBG radiotherapy with chemotherapy after induction for newly diagnosed
Dr Greg Yanik (University of Michigan) presented preliminary results of the NANT (New Approaches to Neuroblastoma Therapy) NANT-2001-02 phase 2 MIBG + CEM (131I-MIBG radiotherapy with carboplatin, etoposide, and melphalan) stem cell transplant trial on June 23rd 2010 at the Advances in Neuroblastoma Research ...
CNCF 2010 ~ Dr Peter Zage on 3F8 phase II randomized trial
Dr Peter Zage from MD Anderson in Houston TX gave a presentation at the Children’s Neuroblastoma Cancer Foundation (CNCF) conference Saturday July 10, 2010 on the 3F8 randomized trial:
A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients (NCT00969722)
This trial is funded by ...
ANR 2010: MIBG avidity, tandem transplant (Korea), and ch14.18 (Germany) updates
MIBG non-avid at diagnosis = better outcome?
POC39 (p. 211) Neuroblastomas with non-avid I-123 MIBG scan and negative urinary catecholamine secretion: A single institute’s experience
PL30 (p. 102) Analysis of MIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma. A Children’s Oncology Group (A3973) report
Dui Yen Soh, Sylvain Baruchel, and Meredith Irwin at Sick Kids in ...
